Table 3.
Patient clinical characteristics
| Patient ID no. | Infused VSTs | HLA matching | Viral disease | Reduction in immuno-suppression | Prior antiviral(s) | Duration prior antiviral therapy | Antiviral drug intolerance | CMV resistance | Change in antiviral post-VST | Response by 6 wk | Overall outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3910 | C6790 | 2/8 | No | No | Ganciclovir | 17 | No | No | No | CR | Sustained CR |
| 3944 | C6798 | 4/8 | No | No | Leflunomide | 94 | AKI, cytopenia | Yes | No | CR | Sustained CR |
| 3976 | C6798 | 6/8 | No | Yes, reduction in tacrolimus between wk 4 and 6 | Foscarnet, ganciclovir | 14 | Renal tubulopathy | Yes (U97 mutation) | No | CR | Sustained CR after second infusion |
| 3762 | C6808 | 5/8 | CMV retinitis | No | None | Unable to tolerate | Poor graft function | Not done | Yes, ganciclovir administered for 1 wk | CR | Sustained CR |
| 3967 | C6823 | 2/8 | CMV colitis (diarrhea) | No | Foscarnet | 211 | AKI | Yes (U97 mutation) | No | PR | Died of renal failure and AdV infection |
| 4091 | C6790 | 5/8 | No | No | Foscarnet, cidofovir, leflunomide | 29 | AKI | Not done | No | CR | Died of renal failure |
| 4115 | C6834 | 5/8 | No | No | Foscarnet | 24 | AKI | Not done | No | CR | Sustained CR |
| 4170 | C6790 | 3/8 | No | No | Ganciclovir, foscarnet | 42 | Pancreatitis | No | No | CR | Sustained CR |
| 4134 | C6798 | 5/8 | CMV colitis (diarrhea) | No | Foscarnet, ganciclovir | 17 | No | Not done | No | PR | Sustained CR |
| 4201 | C6814 | 3/8 | No | Yes, tacrolimus taper initiated before VST infusion | Foscarnet, ganciclovir | 41 | No | No | No | PR | Sustained CR after third infusion |
AdV, adenovirus; AKI, acute kidney injury; PR, partial response.